Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer, according to a large randomized clinical trial conducted by researchers from SWOG Cancer Research Network.
GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
